홈 › 버킷 림프종 › 뉴욕 › New York City
NY New York City의 버킷 림프종 임상 시험
버킷 림프종 관련 연구 13개가 New York City 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
피험자 모집 중3상
- Memorial Sloan Kettering Cancer Center, New York
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중2상
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- 외 1개
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
피험자 모집 중3상
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
피험자 모집 중2상
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
피험자 모집 중3상
- David H. Koch Center for Cancer Care, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
피험자 모집 중1/2상
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중1상
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중2상
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
피험자 모집 중3상
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- 외 2개
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
피험자 모집 중1/2상
- Research Site, New York
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
피험자 모집 중2상
- Memorial Sloan Kettering Cancer Center, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
피험자 모집 중1상
- Weill Cornell, New York
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
피험자 모집 중1/2상
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
다른 도시의 버킷 림프종 시험
- Houston, TX연구 21개
- Philadelphia, PA연구 16개
- Milwaukee, WI연구 16개
- Chicago, IL연구 15개
- Cincinnati, OH연구 13개
- Atlanta, GA연구 12개
- Aurora, CO연구 11개
- Seattle, WA연구 11개
- Durham, NC연구 10개
- Boston, MA연구 10개
- Kansas City, MO연구 10개
- Los Angeles, CA연구 10개
New York City의 다른 연구
- 유방암연구 136개
- 비소세포폐암연구 121개
- 암 (전체)연구 109개
- 전립선암연구 103개
- 전이성 암연구 93개
- 대장직장암연구 78개
- 난소암연구 69개
- 폐암연구 60개
- 다발성 골수종연구 60개
- 췌장암연구 60개
- 자궁내막암연구 52개
- 급성 골수성 백혈병연구 51개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.